Bookmark with More

Multiplexed Protein Detection Webinar

Visit the website

Topic: Use of multiplex technologies for measuring biomarkers in early non-clinical safety assessment
Speaker: Philip Hewitt, Ph.D., Imperial College, London, Head of Early Non-clinical Safety (Liver and Kidney) at Merck Serono’s Institute of Toxicology
Date: May 3, 2013
Time: 10:00 am - 11:00 am (EDT)

We invite you to participate in our upcoming webinar featuring our MILLIPLEX® MAP toxicity biomarker panels, where you'll learn how multiplexed detection of toxicologically relevant proteins has been found to accelerate drug development by providing earlier predictions of drug outcomes in pre-clinical species and humans. We will cover two case studies:

(1) Are the FDA/EMA qualified acute nephrotoxicity biomarkers relevant for longer, subacute exposure in rats?

(2) Measurement of a potential “cytokine storm” in the dog (in vitro and in vivo). We will discuss the potential impact of multiplexed protein assays (such as MILLIPLEX® MAP assays using Luminex® xMAP® technology) on non-clinical safety assessment.

Dr. Phil Hewitt will answer your questions on topics including:

  • Using biomarkers in drug development and safety assessment
  • Getting the most information from each sample
  • The ease of incorporating MILLIPLEX® MAP Toxicity and Cytokine Biomarker Panels into your workflow